Drug Profile
Research programme: autologous cultured GI tissue cells - inRegen
Alternative Names: Neo-GI Augment; Neo-oesophageal implant - inRegenLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Tengion
- Developer inRegen
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (Parenteral, Implant)
- 10 Jul 2013 Preclinical trials in Gastrointestinal disorders in USA (Parenteral)
- 20 Sep 2010 Early research in Gastrointestinal disorders in USA (Parenteral)